



## Kiadis Pharma continues to provide Rhitol

To participating physicians during completion of current clinical study

FINAL – Amsterdam, November 19, 2007 – Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete at the end of this year. Kiadis Pharma anticipates applying for and starting a phase III study in 2008.

*Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites participating in the ongoing phase II trial were left without treatment alternatives following the announcement of the enrolment closure. The interest these physicians show in using our product for new patients is very encouraging and we are very pleased that we can support them by providing Rhitol through special provisions, until the start of the phase III clinical trial."*

The physicians interested in enabling new patients to receive treatment with Rhitol will obtain regulatory authorization from the appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid refractory Graft versus Host Disease (GvHD) who have exhausted other treatment options. Chronic GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. The immune cells from the donor graft cause GvHD by attacking the patient's tissues and organs. There are two forms of GvHD: acute GvHD appears within 100 days after transplantation and chronic GvHD begins anytime after that period. Immune-suppressant drugs, such as steroids, are generally used to treat chronic GvHD. The disease can become a life-threatening condition when standard treatment cannot control its progression as the patient either does not respond to steroid treatment or develops severe side effects due to their use. Extensive chronic GvHD affects multiple organs and tissues and results in diminished quality of life for patients.

### About Rhitol

Rhitol is under development as a treatment for steroid resistant or intolerant chronic GvHD in patients who have received allogeneic bone marrow transplantation. Rhitol is not registered yet, but clinical trials are currently being conducted to demonstrate its safety and efficacy. Rhitol uses a small molecule that selectively eliminates reactive autoimmune cells and is designed to result in immune modulation within the patient, restoring immune tolerance and attempting to achieve disease remission.

### About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical company with four products in different phases of clinical development. The company develops products that offer new treatment options for terminally ill cancer patients and address significant unmet medical needs. Key areas for Kiadis Pharma are clinical indications in blood cancers and solid tumours. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit [www.kiadis.com](http://www.kiadis.com)

**For more information please contact:**

Kiadis Pharma B.V.  
Eefje Simpelaar  
Director Communications  
Email: e.simpelaar@kiadis.com  
Tel: +31 208884802  
Mob: +31 610829344

*This announcement is not an offer to sell or a solicitation of any offer to buy the securities of Kiadis Pharma (the "Company", and such securities, the "Securities") in the United States or in any other jurisdiction.*

*The Securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of the Company is being made in the United States.*

*This communication is directed only at (i) persons outside the United Kingdom, or (ii) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Any investment or investment activity to which this communication relates is available only to and will be engaged in only with such persons. Persons within the United Kingdom who receive this communication (other than persons falling within (ii) and (iii) above) should not rely on or act upon this communication.*

*Certain statements in this announcement are forward-looking statements. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from those expressed and implied by the forward-looking statements*